| abstract |
One or more cyclic heterocyclic compounds of formula (Ia) to (Ie) ltalos bearing the "nb" substituents of the present invention and pharmaceutically acceptable salts thereof are compounds. and Q 2, independently of one another, is a phenyl ring or a 5-6 membered aromatic sheterocyclic ring system or an 8-10 membered bicyclic aromatic scarbocyclic ring, an aromatic heterocyclic ring or an aromatic carbocyclic ring and an aromatic s heterocyclic ring choose "k"; Y is nitrogen or carbon; Z is methyl, nitrogen, -C (OCH) -C (CH) =, -C (NH) =, -C (OH) = or -C (F) =; U is selected from the group consisting of -R or -W ltal nos; A, B and C are -O-, -CHR'-, -CHR4-, -NR'-, -NR4- or -S- These compounds are inhibitors of the p38 enzyme, which is a mammalian protein kin z. The p38 enzyme plays an important role in cell death and in the responses to extracellular ris stimuli. The present invention also provides a process for the preparation of these inhibitors. Also included are pharmaceutical compositions containing these inhibitors and methods for treating or preventing "nb" disorders, diseases or conditions associated with these pharmaceutical compositions. These include disorders, diseases or conditions including cancerous, inflammatory, autoimmune, proliferative, infectious, viral and neurodegenerative diseases, and destructive bone diseases. SHE |